Format

Send to

Choose Destination
J Neurosurg. 2018 Mar;128(3):695-700. doi: 10.3171/2016.11.JNS161212. Epub 2017 Apr 14.

Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.

Author information

1
Departments of1Neurosurgery.
2
2Pathology, and.
3
3Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California.

Abstract

OBJECTIVE Glioblastoma (GBM) is the most prevalent and the most aggressive of primary brain tumors. There is currently no effective treatment for this tumor. The proteasome inhibitor bortezomib is effective for a variety of tumors, but not for GBM. The authors' goal was to demonstrate that bortezomib can be effective in the orthotopic GBM murine model if the appropriate method of drug delivery is used. In this study the Alzet mini-osmotic pump was used to bring the drug directly to the tumor in the brain, circumventing the blood-brain barrier; thus making bortezomib an effective treatment for GBM. METHODS The 2 human glioma cell lines, U87 and U251, were labeled with luciferase and used in the subcutaneous and intracranial in vivo tumor models. Glioma cells were implanted subcutaneously into the right flank, or intracranially into the frontal cortex of athymic nude mice. Mice bearing intracranial glioma tumors were implanted with an Alzet mini-osmotic pump containing different doses of bortezomib. The Alzet pumps were introduced directly into the tumor bed in the brain. Survival was documented for mice with intracranial tumors. RESULTS Glioma cells were sensitive to bortezomib at nanomolar quantities in vitro. In the subcutaneous in vivo xenograft tumor model, bortezomib given intravenously was effective in reducing tumor progression. However, in the intracranial glioma model, bortezomib given systemically did not affect survival. By sharp contrast, animals treated with bortezomib intracranially at the tumor site exhibited significantly increased survival. CONCLUSIONS Bypassing the blood-brain barrier by using the osmotic pump resulted in an increase in the efficacy of bortezomib for the treatment of intracranial tumors. Thus, the intratumoral administration of bortezomib into the cranial cavity is an effective approach for glioma therapy.

KEYWORDS:

AMC = 7-amino-4-methylcoumarin; BBB = blood-brain barrier; GBM = glioblastoma; IT = intratumorally; IV = intravenously; MTT = monotetrazolium; Velcade; bortezomib; brain; glioma; intracranial delivery; mice; oncology

PMID:
28409734
DOI:
10.3171/2016.11.JNS161212

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center